United States: Podcast: FDA Holds Public Hearing On Manufacturer Communication Of Scientific And Medical Information

In this podcast, Doug Hallward-Driemeier, chair of Ropes & Gray's appellate and supreme court practice, moderates a discussion with partner Kellie Combs and senior counsel Alan Bennett about the FDA's open hearings regarding off-label communications. 

Transcript:

Doug Hallward-Driemeier: I'm Doug Hallward-Driemeier, Chair of Ropes & Gray's appellate and Supreme Court practice. I'm here today with partner Kellie Combs and senior counsel Alan Bennett, from our FDA Life Sciences practice, to discuss this week's open FDA hearings regarding off-label communications. We've seen a growing concern among pharmaceutical and medical device manufacturers over the degree to which FDA regulates off-label communication. And, Kellie, you testified at the FDA open hearings on November 9, on behalf of the Medical Information Working Group, a coalition of more than a dozen drug and device manufacturers seeking changes to FDA's regulatory scheme. So, tell us about the hearings, about your testimony, and whether you think it was a significant step toward meaningful reform.

Kellie Combs: Sure, Doug, I'd be happy to. The MIWG has been urging the FDA for nearly ten years now to clarify its regulatory framework governing manufacturer speech, and in 2014 the agency actually promised to issue guidance later that year, in four critical areas: scientific exchange, payer communications, responses to unsolicited requests and dissemination of clinical practice guidelines. So, the agency also promised, at that time, to engage in a comprehensive review of its policies to determine whether any revisions were necessary in view of First and Fifth Amendment limitations. Unfortunately, more than two years have now passed, and we haven't had any meaningful action from FDA. So, at the hearing, we emphasized that because off-label use is common that it's absolutely essential there be clear pathways for manufacturers to actually provide scientific and medical information about those off label uses to healthcare professionals and to payers. And, then we also described the First and Fifth Amendment principles that the agency needs to be mindful of in this space. In particular, that FDA can't restrict manufacturers from providing truthful and non-misleading information, even if it is off-label, unless those restrictions are clear, precise and narrowly drawn to advance a compelling interest. And, then finally, we urged the agency to issue those four overdue guidance documents immediately so that industry could finally have clarity on how to communicate in those areas and so that valuable information could be shared to inform treatment decisions.

DHD: And I know that you had prepared remarks, as did the other speakers, but I also know that, somewhat unexpectedly, it was a fairly live active panel from the FDA, and so they were asking questions. So, did their questions give you any hint of where you think FDA is going with this?

KC: You know, I think I and many of us were pleasantly surprised at how engaged the agency actually was. The panelists asked really thoughtful, substantive questions of almost all the speakers, and it was really clear from the questions that the panel, number one, recognizes that there is value in off-label communications, and that additional clarity and flexibility is needed. But, number two, the panelists really appeared to be grappling with how to implement the clarity and flexibility that everyone knows is needed.

Alan Bennett: Kellie, I would add something to that. As you said, the panel was quite involved, and I think they were probing the outer boundaries of our arguments. Questions like do we view the rules for consumer audiences and professional audiences as the same, who judges what's true, and what's the appropriate standard for evaluating data are all designed to see how far free speech advocates are willing to push the arguments.

KC: Yeah, Alan, I think that's a really good point, and you know, Doug, I would be interested in your view on this. So one of the questions we heard repeatedly over the course of the two days, is that, you know the panel has expressed some concern that off-label communications could ultimately lead to patient harm, and that as a result there should be greater restrictions on the extent to which manufacturers could share off-label information. How would you respond to that concern?

DHD: Because I look at this from a constitutional perspective, I think that the FDA is looking at this sort of from the wrong angle. They're trying to ask what are the justifications for allowing the speech, when what the constitution requires is that you look at what are the justifications the government has to limit this speech. And, they're limiting speech that is actually quite valuable, and, as a consequence, doctors are less informed as they make decisions about their patient care than they should be. But the fact that the speech is First Amendment protected doesn't mean that the government doesn't have any role to play, or that all speech, necessarily, is going to get out, even really unfounded claims. The government has a role, but it has to justify restrictions. And right now what the government is doing is imposing limitations on manufacturers' ability to speak, such as requiring they have two well-controlled randomized trials for anything they want to say, that the government itself does not apply to its own speech. FDA, CDC, ACIP, all rely on much different evidence and much lesser forms of evidence than it demands of the manufacturers, and that is what the First Amendment really doesn't allow, is that the government assigns itself the role of arbiter of truth, and setting up a rule that manufacturers can't speak unless the government allows it to. So I think that the meeting is going to be very important, to the extent that it sort of really compels FDA to grapple with that. I wanted to turn it back, though, to Alan, because you've been at this for 25 years. You have seen a long history of development here. I want to get your sense of where we have we come from, and where do you see this going.

AB: Well, it has been a long while, Doug, and it's interesting to look back. I think you have to look at that question in a couple of different ways. As a strictly regulatory matter, change, in fact, has been minimal over the last 25 years. FDA's policies haven't budged, and the agency strongly resists efforts to modify those policies and guidance, regulation or law. I would say, at a more practical level, the agency's interest in forcing some of those policies has been curtailed in recent years, in certain circumstances. For example, if a company has strong, adequate and well-controlled studies about an endpoint that's consistent with the label, it might consider options in a way that it might not have 5 or 10 years ago. While the regulatory scheme has not budged much, on a policy level I've never seen the agency under such immense pressure to make changes. Some of this comes from the way information is disseminated today, and the increasing need for information from physicians, from doctors, from payers. But we also can't forget the outside pressure that the courts are bringing by applying First Amendment principles to the regulatory system. I don't think the current set of rules and policies can survive. A new system is being born, based on truthful, non-misleading speech accompanied by adequate disclosures, but we don't know yet exactly what the contours of that system will be. That will make the next several years quite interesting for those who practice in this area.

DHD: Interesting, indeed, and we will keep you informed of future developments. Thank you, Alan and Kellie, for sharing your insights, and thank you for listening.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.